Folgen

  • Why 1 BILLION people can't get malaria
    Aug 1 2026

    The Duffy antigen gene (DARC) mutation and GATA1 transcription factor binding site explain how a single T-46C promoter variant causes the Duffy-negative blood type and natural resistance to Plasmodium vivax malaria.


    Paper discussed in the video:

    Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy–negative individuals

    https://www.nature.com/articles/ng0695-224


    Tools I use to make these type of videos:

    https://e2g.stanford.edu/

    Mehr anzeigen Weniger anzeigen
    5 Min.
  • The ZPBP2 Asthma Gene Explained in 9 Minutes
    Jul 25 2026

    Rs12936231, one tiny DNA switch on chromosome 17 raises your risk of asthma, type 1 diabetes, and 3 other autoimmune diseases at once. We trace the real biobank data live and reveal how a weakened CTCF boundary explains it all.


    Paper discussed in the video:

    Allele-Specific Chromatin Remodeling in the ZPBP2/GSDMB/ORMDL3 Locus Associated with the Risk of Asthma and Autoimmune Disease

    https://doi.org/10.1016/j.ajhg.2009.08.007


    Tools I use to make these type of videos:

    https://platform.opentargets.org/

    https://e2g.stanford.edu/

    https://github.com/statgen/pheweb

    https://smart.embl.de/smart/change_mode.cgi

    Mehr anzeigen Weniger anzeigen
    9 Min.
  • Finnish? this mutation → brain cancer
    Jul 17 2026

    A single DNA letter (rs55705857) makes Finns 6x more likely to get brain cancer. We trace it live from FinnGen PheWAS to AlphaFold to reveal how it hijacks the MYC oncogene.

    Paper discussed in the video:

    A noncoding single-nucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation https://www.science.org/doi/full/10.1126/science.abj2890

    Tools I use to make these type of videos:

    https://platform.opentargets.org/

    https://e2g.stanford.edu/

    https://github.com/statgen/pheweb


    Mehr anzeigen Weniger anzeigen
    7 Min.
  • The Killer Gene That FOUGHT BACK
    Sep 29 2025

    In this deep dive, we break down the journey of the PIM Kinase target. We explore the complex PIM1 molecular mechanism, examine why first-generation pan-PIM inhibitors like AZD-1208 faced safety issues and a lack of monotherapy efficacy, and reveal the final clinical verdict of the Terminated and Completed Phase 1 studies.


    📖 Video Chapters:

    0:00 - Intro

    1:05 - Biobanks Associations for PIM1

    22:18 - PIM1 Gene

    39:00 - PIM1 Protein

    52:52 - PIM1 Known Drugs and Clinical Trials

    Mehr anzeigen Weniger anzeigen
    1 Std. und 3 Min.
  • The Mysterious Gene Behind Blood Clots
    Sep 24 2025

    Disclaimer: This video is for educational purposes only and should not be used for medical diagnosis or treatment decisions. Always consult with healthcare professionals for medical advice.

    In this episode, we explore the association between the PEAR1 gene and various platelet disorders. Using data and research, we aim to explain the significance of platelet count and the effects of thrombocytopenia and low platelets in these conditions. This includes genetic analysis of the genome.

    #genetics #blood #platelets

    Mehr anzeigen Weniger anzeigen
    1 Std. und 7 Min.
  • KGWAS: novel genetics discovery enabled by massive functional genomics knowledge graph
    Sep 22 2025
    KGWAS is a novel geometric deep learning method that leverages a massive functional knowledge graph across variants and genes to significantly improve detection power in small-cohort GWASs. Thank you, Kexin Huang and Martin Jinye Zhang, for joining me on this one.Preprint:https://www.medrxiv.org/content/10.11...GitHub Page:https://github.com/snap-stanford/KGWASOfficial Website:https://kgwas.stanford.edu/📖 Video Chapters:0:00 - Introduction to Rare Disease Genetics Problem0:54 - Welcome & Paper Overview1:22 - What is KGWAS? The Elevator Pitch2:41 - Why Finding More GWAS Hits Matters4:46 - Origin Story: Collaboration with GSK6:09 - Knowledge Graph Architecture Overview7:36 - Building the Variant-Gene-Pathway Network9:55 - Handling Linkage Disequilibrium (LD) Challenges13:55 - Training the Large-Scale Graph Neural Network14:16 - Model Training Requirements and Scalability15:22 - Open Source Availability and Accessibility16:05 - Scaling to Whole Genome Analysis17:12 - Figure 2: Validation Through Simulations18:24 - UK Biobank Downsampling Experiments20:04 - Precision-Recall Performance Results21:00 - Figure 3: Real-World Disease Applications21:38 - Ulcerative Colitis Case Study Example22:48 - Experimental Validation of Ulcerative Colitis Discovery24:03 - Myasthenia Gravis Case Study Analysis26:10 - Knowledge Graph Component Analysis and Ablation Studies27:54 - Tissue-Specific vs Context-Agnostic Approaches32:03 - Figure 4: Network Interpretation and Attention Mechanisms36:30 - Alzheimer's Disease Network Visualization40:01 - Drug Development Applications and Implications41:15 - Post-GWAS Era Applications and End-to-End Solutions43:01 - Figure 5: Compatibility with Existing GWAS Tools48:16 - Population Diversity and Cross-Ancestry Applications49:41 - Future Directions and Technical Improvements52:16 - Input/Output Requirements and Computational Resources54:28 - Website Demo and Interactive Features56:59 - PhD Student Advice and Research Philosophy59:36 - Closing Remarks
    Mehr anzeigen Weniger anzeigen
    1 Std.
  • Low overlap of transcription factor DNA binding and regulatory targets
    Aug 18 2025

    This podcast was made possible by CIUT-FM 89.5, University of Toronto Community Radio. For more content visit https://ciut.fm/


    Link to the paper:

    https://www.nature.com/articles/s41586-025-08916-0


    Join me in a conversation with two of the authors, Lakshmi Mahendrawada and Steven Hahn.

    Mehr anzeigen Weniger anzeigen
    1 Std. und 9 Min.
  • K562 cell Masterclass | Dr. Tom Karagiannis
    Jul 17 2025

    This podcast was made possible by CIUT-FM 89.5, University of Toronto Community Radio. For more content, visit https://ciut.fm/


    Join us for this comprehensive masterclass episode as we explore the fascinating world of K562 cells with Dr. Tom Karagiannis, who has worked with these remarkable cells for almost three decades. From his first encounter with them as a young researcher in 1996 during the exciting era of targeted therapy development, Dr. Karagiannis shares both the scientific breakthroughs and practical realities of working with these "weeds" of the lab.



    📖 Video Chapters:

    0:00 - The 1917 Origin Story: A Woman's Legacy

    2:40 - Interview Begins: Dr. Tom Karagiannis on K562 Basics

    5:42 - The 1990s Gleevec Revolution: Why K562 Cells Became Essential

    7:10 - The Lozio Discovery: From Patient to Immortal Cell Line

    8:48 - What Makes K562 Cells Special: Continuous Growth vs Normal Cells

    10:36 - Cell Culture Evolution: From Glass Pipettes to Modern Labs

    12:18 - Historical Context: HeLa Cells to Cancer Virus Research

    14:26 - The Philadelphia Chromosome: Understanding the Genetic Driver

    17:06 - Gleevec Revolution: The First Targeted Cancer Therapy

    19:48 - K562 Cell Genetics: The Near-Triploid Puzzle

    21:00 - Cell Differentiation: Research Applications and Advantages

    24:08 - Transferrin Receptor Research: Dr. Tom's Early Work

    28:37 - K562 Cells as "Weeds": Why They're So Easy to Grow

    33:08 - Evolution of Cancer Research: From Targeted Therapy to CAR-T

    35:42 - Personal Research Stories: Genetic Discoveries and Insights

    36:03 - Genetic Discoveries: Novel Chromosomes and Cellular Evolution

    42:27 - Drug Resistance Studies: Creating Doxorubicin-Resistant Cell Lines

    44:12 - Epigenetic Research: HDAC Inhibitors and Combination Therapies

    49:16 - Combination Therapy Mechanisms: How HDAC Inhibitors Enhance Chemotherapy

    50:40 - Drug Resistance Reality: Gleevec Limitations and Cancer Stem Cells

    53:54 - K562's Continued Value: Why Genetic Drift Doesn't Diminish Research Utility

    57:27 - PhD Advice

    Mehr anzeigen Weniger anzeigen
    1 Std.